Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis

Rheumatoid Arthritis

Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study

Semin Arthritis Rheum.

Montastruc F, Renoux C, Hudson M, Dell'Aniello S, Simon TA, Suissa S

doi: 10.1016/j.semarthrit.

Rheumatoid Arthritis

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Ann Rheum Dis.

Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC

doi: 10.1136/annrheumdis-

Further Publications Rheumatology

Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model

Rheumatology (Oxford)

Krabbe S, Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Jarbøl DE, Østergaard M, Hetland ML

doi: 10.1093/rheumatology/keaa876

Rheumatoid Arthritis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Ann Rheum Dis.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB

doi: 10.1136/annrheumdis-

Psoriasis

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

JAMA Dermatol.

Dommasch ED, Kim SC, Lee MP, Gagne JJ

doi: 10.1001/jamadermatol.

Further Publications Rheumatology

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study

Arthritis Rheumatol

Shalev Rosenthal Y, Schwartz N, Sagy I, Pavlovsky L

doi: 10.1002/art.41946

Psoriasis

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group

doi: 10.1111/bjd.17036.

PsoriasisPsoriatic Arthritis

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis

JAMA Dermatol.

Vaengebjerg S, Skov L, Egeberg A, Loft ND

doi: 10.1001/jamadermatol.2020.0024.

PsoriasisRheumatoid Arthritis

Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis

Semin Arthritis Rheum.

Baganz L, Listing J, Kekow J, Eisterhues C, Wassenberg S, Zink A, Strangfeld A

doi: 10.1016/j.semarthrit.2019.07.004.

Related content

Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

Psoriatic arthritis incidence among patients receiving biologic medications for psoriasis: A nested case control study

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis

Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis